risankizumab
Sign in to saveAlso known as BI 655066, BI-655066, Skyrizi
Risankizumab ( ), sold under the brand name Skyrizi ( ), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.
In the Vinony graph
Vinony's link graph records 382 inbound references to risankizumab, and connects out to monoclonal antibody, fusion protein and humanized antibody.
It sits within the topics Antipsoriatics, Chemicals that do not have a ChemSpider ID assigned and Drugs developed by AbbVie.
Vinony links it to 16 Wikipedia language editions.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu
- Drug.target
- Interleukin 23A
- Drug.tradename
- Skyrizi
- Drug.MedlinePlus
- a619035
- Drug.DailyMedID
- Risankizumab
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AC18
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 1 more fact
- subject has role
- monoclonal antibody
via Wikidata · CC0
~3 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Adverse effects
- History
- Clinical trials
- Psoriasis
- References
- External lists
Risankizumab ( ), sold under the brand name Skyrizi ( ), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.
The most common side effects include upper respiratory infections (nose and throat infection)..
Excerpted from Wikipedia’s “risankizumab” article, available under the CC BY-SA 4.0 licence.